QMPSF is sensitive and specific in the detection of NPHP1 heterozygous deletions by Jávorszky, Eszter et al.
Clin Chem Lab Med 2017; 55(6): 809–816
Eszter Jávorszky*, Vincent Morinière, Andrea Kerti, Eszter Balogh, Henriett Pikó,  
Sophie Saunier, Veronika Karcagi, Corinne Antignac and Kálmán Tory*
QMPSF is sensitive and specific in the detection of 
NPHP1 heterozygous deletions
DOI 10.1515/cclm-2016-0819
Received September 12, 2016; accepted November 8, 2016; previously 
published online December 21, 2016
Abstract
Background: Nephronophthisis, an autosomal recessive 
nephropathy, is responsible for 10% of childhood chronic 
renal failure. The deletion of its major gene, NPHP1, with a 
minor allele frequency of 0.24% in the general population, 
is the most common mutation leading to a monogenic form 
of childhood chronic renal failure. It is challenging to detect 
it in the heterozygous state. We aimed to evaluate the sen-
sitivity and the specificity of the quantitative multiplex PCR 
of short fluorescent fragments (QMPSF) in its detection.
Methods: After setting up the protocol of QMPSF, we vali-
dated it on 39 individuals diagnosed by multiplex liga-
tion-dependent probe amplification (MLPA) with normal 
NPHP1 copy number (n = 17), with heterozygous deletion 
(n = 13, seven parents and six patients), or with homozy-
gous deletion (n = 9). To assess the rate of the deletions 
that arise from independent events, deleted alleles were 
haplotyped.
Results: The results of QMPSF and MLPA correlated per-
fectly in the identification of 76 heterozygously deleted and 
56  homozygously deleted exons. The inter- experimental 
variability of the dosage quotient obtained by QMPSF 
was low: control, 1.05 (median; range, 0.86−1.33, n = 102 
exons); heterozygous deletion, 0.51 (0.42−0.67, n  = 76 
exons); homozygous deletion, 0 (0−0, n = 56 exons). All 
patients harboring a heterozygous deletion were found to 
carry a hemizygous mutation. At least 15 out of 18 dele-
tions appeared on different haplotypes and one deletion 
appeared de novo.
Conclusions: The cost- and time-effective QMPSF has a 
100% sensitivity and specificity in the detection of NPHP1 
deletion. The potential de novo appearance of NPHP1 
deletions makes its segregation analysis highly recom-
mended in clinical practice.
Keywords: copy number variation; deletion; nephronoph-
thisis; NPHP1; quantitative multiplex PCR of short fluores-
cent fragments (QMPSF).
Introduction
Nephronophthisis is an autosomal recessive kidney dis-
order leading to interstitial fibrosis and tubular basement 
membrane alterations. It is a common cause of child-
hood end-stage renal disease, responsible for 10% of the 
cases. Its classical symptoms, polyuria and  polydipsia, 
are typically not severe enough for the parents to seek 
medical help. Therefore, when no extra-renal involve-
ment is associated, it typically remains unrecognized 
till the onset of end-stage renal disease [1]. Genetically, 
it is highly heterogeneous with 20 genes identified thus 
far [2]. Among them, NPHP1 (OMIM #256100) is the most 
frequently mutated due to a recurrent deletion involving 
the entire gene [3]. This deletion results from an unequal 
recombination between two directly oriented low-copy 
repeats, the size of which (~ 45 kb) has not yet allowed 
the identification of the breakpoint [4]. This mechanism 
makes the NPHP1 deletion the most common mutation in 
monogenic forms of childhood chronic renal failure with 
an allele frequency of 0.24% in the general  population [5].
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In the majority of the patients, the NPHP1 deletion is 
present in the homozygous state making its detection by 
PCR easily feasible [6]. Nevertheless, when  trans-associated 
to a point mutation or in carrier parents and siblings, its 
detection in the heterozygous state may be challenging. 
As the localization of the breakpoint is unknown, a break-
point-spanning PCR is not feasible. Therefore, in clinical 
practice and even in medical reports, the detection of the 
heterozygous deletion is either neglected or necessitates 
labor-intensive and expensive methods such as compara-
tive genomic hybridization, fluorescent in situ hybridiza-
tion or multiplex ligation-dependent probe amplification 
(MLPA) [7–9].
The time- and cost-effective method of quantitative 
multiplex PCR of short fluorescent fragments (QMPSF) 
has been widely used in the identification of copy number 
variations (CNV) [10–18]. We adapted it for the NPHP1 
deletion screening, and here we show its perfect sensitiv-
ity and specificity, and the importance of the screening in 
clinical practice.
Materials and methods
Patients
Forty individuals from 28 families (31 patients and 9 parents), diag-
nosed between 2010 and 2015 at the 1st Department of Pediatrics, 
Semmelweis University Budapest with potential NPHP1-associated 
nephronophthisis – i.e. juvenile nephronophthisis, either isolated 
or with mild Joubert syndrome or late-onset retinopathy [19] – were 
investigated. Two families were multiplex with two and three affected 
children. Two families were consanguineous. All families gave 
informed consent, and the study was approved by the Local Research 
Ethic Committee (TUKEB 6569-0/2010-1018EKU).
DNA extraction
DNA was extracted based on proteinase K digestion followed by 
high-sodium chloride treatment to precipitate proteins. DNA con-
centration was measured by NanoDrop™ 1000 Spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA, USA) and was diluted with 
TE buffer (10 mM Tris-HCl pH 8.2, 1 mM EDTA) to achieve a final con-
centration of 10 ng/μL for QMPSF and 20 ng/μL for MLPA.
Multiplex ligation-dependent probe amplification assay
All samples were analyzed by the NPHP1-specific reagent kit, 
covering all 20 exons (SALSA MLPA P387 NPHP1 probemix; 
MRC-Holland, Amsterdam, The Netherlands), according to the 
manufacturer’s instructions, with 100 ng genomic DNA. Fragment 
analysis was performed on ABI 3500 Genetic Analyzer (Applied 
Biosystems,  Foster City, CA, USA), and the results were evalu-
ated using Peak  Scanner Software (Thermo Fischer Scientific) and 
 Coffalyser ( MRC-Holland).
Validation of the identified deletions
All NPHP1 deletions – identified by MLPA – were confirmed by a 
second method in the affected individuals. Homozygous deletions 
were validated by PCR as previously described [6]. Patients with 
heterozygous deletion were screened for point mutations in the cod-
ing regions and the splicing junctions of NPHP1 (NM_000272) by 
Sanger sequencing [4]. The hemizygous state of the point mutations 
was confirmed by haplotype and segregation analysis. A partial 3′ 
 deletion was confirmed by array CGH.
Quantitative multiplex PCR of short fluorescent 
 fragments (QMPSF)
All samples were investigated by QMPSF. Short, 120- to 321-bp-long 
fragments of six NPHP1 (2q13) exons [3, 6, 9, 12, 15, 19] together with 
two control regions of HSD17B3 (9q22.32) and USH2A (1q41) were 
amplified by multiplex PCR (Table 1, Figure 1).
The conditions were set up in a patient with a heterozygous 
deletion and in three control subjects, two of whom was diagnosed 
with an HNF1B deletion and one with amyloidosis, who was also con-
firmed by MLPA to have a normal NPHP1 copy number. The multiplex 
PCR was performed in 30 μL of reaction master mixture containing 
0.2  mmol/L of each dNTP, 1.5  mmol/L MgCl2, 0.6 U Immolase DNA 
polymerase (ImmoMix™, Bioline Inc.), and 0.1–0.4 μmol/L of each 
primer as specified in Table 1. Twenty-nanogram genomic DNA (2 μL) 
was added to yield a final volume of 32 μL. The initial denaturation 
(95 °C for 12 min) was followed by 26 cycles of amplification (95 °C 
for 45 s, 60 °C for 45 s, 72 °C for 45 s) and a final extension (72 °C for 
10 min). This limited number of cycles stops the amplification in the 
exponential phase keeping the amount of the PCR product propor-
tional to the original amount of the targeted sequence, thus allow-
ing the quantification of the target sequence relative to the control 
regions. All forward primers were labeled with 6-FAM fluorophore 
and universal extensions were added to the 5′ end of both forward 
and reverse primers [13, 16, 20]. Fragment analysis was carried out in 
the same way as for MLPA.
Four controls (three negative and one with a known heterozy-
gous deletion identified by MLPA) were run in each assay. Results of 
QMPSF were analyzed only if the peak height of both HSD17B3 and 
USH2A control regions were above 2000 relative fluorescence units. 
To determine the gene dosage for each amplified region, dosage 
quotient (DQ) was calculated: the ratio of the target peak area and 
the average of HSD17B3 and USH2A peak areas was determined for 
each patient and was subsequently divided by the controls’ average 
ratio. This gives a theoretical DQ of 1.0 for two NPHP1 copies and 0.5 
for a heterozygous deletion [10, 12, 21, 22]. Following the criteria of 
the MLPA protocol, we considered a DQ value between 0.3 and 0.7 to 
reflect a heterozygous deletion and a DQ value between 0.7 and 1.3 to 
reflect a normal copy number [23, 24].
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Table 1: NPHP1-QMPSF primer sequences.
Primer   Primer sequence   Product length, bp   Concentration, μmol/L
NPHP1 3F   CCTGCTCAACGACTGAATGA   136   0.1
NPHP1 3R   TCTATTGCCTGCTTTAACTGGA    
NPHP1 6F   CGGGTGATAGGGAAGCTTTT   225   0.2
NPHP1 6R   TCCACCAACCATCAGGTTTT    
NPHP1 9F   TGCAGAAACATGACTGAAAACA   241   0.4
NPHP1 9R   TGTGTTTTGCCTGTGACAGAA    
NPHP1 12F   AGCCACATGGCAACCTAAAA   200   0.4
NPHP1 12R   CAATGTCCTCAAAGAACACCAA    
NPHP1 15F   ACCTCATGGAGGGATCAACA   321   0.4
NPHP1 15R   GCTACCTCTCAGATGCTTCTATTTG    
NPHP1 19F   TTTCTGTTTGCTCTTTAGAGTTCG   120   0.2
NPHP1 19R   GCAAATATGGAGTTCAGTGTGG    
HSD17B3 11F   AAGGCTGCTCCTGACACACT   186   0.2
HSD17B3 11R   CCTCCATCTTCAGCGGACTA    
USH2A 41F   CCTTTCACCAGAGTCCCAGA   273   0.2
USH2A 41R   CCATGGGCTAAGAGCAGAAG    
Primers of control regions are in bold.
Figure 1: The position of the NPHP1-QMPSF primers (2q13, ENST00000393272.3) as shown by green (forward) and red lines (reverse primers). 
Cen, centrome; Tel, telomere.
Haplotype analysis
The D2S293, D2S340, D2S1893, D2S160, and D2S363  microsatellite 
markers – located outside the NPHP1 deletion – were used for haplo-
type analysis as described previously [25–27].
CGH array
CGH array analysis was performed in a patient who was compound 
heterozygous for two different deletions. A high-resolution genomic 
scan using ISCA plus design array of Nimblegen-Roche containing 
1.4 M probes per subarray (assembly GRCh37/hg19) was performed in 
the DNA sample of the patient. This CGX microarray provides a mean 
average resolution of approximately 15–20  kb. Array CGH analysis 
was performed according to the manufacturer’s protocol. The CGH 
protocol involves independent labeling of the patient (test DNA) and 
the reference genomic DNA (Human Genomic DNA, Promega, Madi-
son, WI, USA) with Cy3 and Cy5 dyes using a NimbleGen Dual-Color 
DNA Labeling Kit (Roche-NimbleGen Inc.). Co-hybridization of these 
DNAs to a NimbleGen CGH array were performed for 72 h at 42 °C. The 
subarrays were scanned on NimbleGen MS 200 microarray scanner 
and data were extracted and analysed using NimbleScan, Signal-
Map, and Deva 1.1 softwares (Roche NimbleGen Inc.).
Results
High rate of NPHP1 deletion in juvenile 
nephronophthisis
Out of the 31 patients with juvenile nephronophthisis, we 
found 16 (52%) patients (14/28 families) to carry NPHP1 
deletion (c.(?_-1)_(*1_?)del) on at least one allele by MLPA 
(Table 2). Nine unrelated patients were homozygous and 
five patients from three families were heterozygous for 
the deletion. The homozygous deletion was confirmed in 
all cases by PCR and all five patients with a heterozygous 
deletion were found to carry a hemizygous point muta-
tion, two of which (c.489delT, p.Phe163Leufs*19, and 
c.656C > A, p.Ser219*) are novel (Figure 2).
Two more unrelated patients were compound het-
erozygous for the classical whole-gene deletion and a 
novel 3′ partial deletion (c.(1810 + 1_1811-1)_(*1_?)del) 
involving the last three [18–20] exons. The latter was 
confirmed by array CGH in one of the two patients (hg19 
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NPHP1 deletions typically result from 
 independent events
Out of the 16 deletions of non-consanguineous families, 
we found one deletion to appear de novo, on the paternal 
allele (F84). The biological paternity was confirmed by 
haplotype analysis (Figure 5).
Furthermore, among the 18  haplotypes with whole 
gene deletion (taking into account the alleles of the two 
consanguineous families as a single allele), we found at 
least 15 different alleles indicating a high rate of inde-
pendent deletions, which is in accordance with previ-
ous results and contrasts the founder 3′ partial deletion 
(Figure 4) [4, 28].
Intra-experimental variability of  
NPHP1-QMPSF is low
We found the intra-experimental variability of NPHP1-
QMPSF – through investigating a control subject and a 
patient with a heterozygous deletion in ten parallel meas-
urements – to be low: DQcontrol = 0.98 (median; quartiles, 
0.96–1.01; range, 0.86–1.09); DQhet.del = 0.51 (median; quar-
tiles, 0.50–0.53; range, 0.45–0.57).
The specificity and sensitivity of QMPSF are 
perfect in the detection of an NPHP1 deletion
There was a clear-cut difference in the DQ values of 17 
control subjects, 13 parents and patients with heterozygous 
deletion, and 9 patients with homozygous deletion in all 
six exons tested (Figures 6 and 7), as also indicated by the 
overall values: DQcontrol = 1.05 (median; quartiles, 0.99–1.08; 
range, 0.86–1.33); DQhet.del = 0.51 (median; quartiles, 0.50–
0.54; range: 0.42–0.67); DQhom.del = 0 (median; range, 0–0).
The two patients with compound heterozygous dele-
tions were properly found to be heterozygous for exons 
Control
F36-1
c.84_87delTTCT
G
G C
06_07_BDxFastSeq50_POP7_1_inj9 sec1600 v
T T T TC G GA A
C T:::: G A A AG G C C
G C T G A A AG G C C
G C T T T T AC G A G
Control
F38-2
G A T T T : TA C G
T A A A AT
G A T T T T CA T
G A T T T T CA T
06_BDxFastSeq50_POP7_1_inj9 sec1600 v
c.489delT
Control
F249-2
A A T A A A G T
A A T A A A G T
F_E02_05_BDxStdSeq50__POP7_12 sec_1.6 kv
c.656C>A
A A T A A A G T
A A T C A A G T
Figure 2: Chromatograms of the hemizygous mutations.
Table 2: NPHP1 mutations of the patients.
Families Paternal allele Maternal allele
F10, F12, F15, F63, F67, F70, F84, F97, F158 dela dela
F36 c.84_87delTTCT, p.Ser29Argfs*4 dela
F38 c.489delT, p.Phe163Leufs*19 dela
F249 c.656C>A, p.Ser219*; delb
F106 Exon 18–20 deletionc dela
F203 dela Exon 18-20 deletionc
adel.: c.(?_-1)_(*1_?)del, bunknown segregation, cc.(1810+1_1811-1)_(*1_?)del or g.(110850451_110862515)_(110888028_110889217)del.
chr2: g.(110850451_110862515)_(110888028_110889217)
del, F106-1, Figure 3) and the second patient (F203-2) was 
shown to carry the same haplotype on the 3′ partially 
deleted NPHP1 allele, reflecting a founder effect (Figure 4).
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3, 6, 9, 12, and 15 deletions and to be deleted on both 
alleles in exon 19. Thus, with the exception of a DQ of 
1.33 erroneously suggesting a duplication for exon 3 in 
a patient with a normal copy number (F2-1), results for 
all exons of all patients correlated perfectly with the 
MLPA results. Thus, all and only the 76 heterozygously 
deleted exons were identified by QMPSF to be deleted 
in the heterozygous state, giving 100% sensitivity and 
100% specificity for the identification of a heterozygous 
deletion.
Discussion
The NPHP1 gene deletion is one of the most common muta-
tions leading to a severe monogenic disorder: it is only 
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Figure 3: Array CGH of patient F106-1.
Compound heterozygous deletion in the NPHP1 gene: while both alleles are deleted (score − 1.05) in the region chr2:g.110862515_110888028 
(on Assembly GRCh37), a heterozygous deletion (score − 0.38) is found in the region g.110888028_110985511. This reflects the trans-
association of the classical whole gene deletion (g.(110850451_110862515)_(110985511_110996482)del) and a partial 3′ deletion 
(g.(110850451_110862515)_(110888028_110889217)del), and defines the 5′ breakpoint of the partial deletion in intron 17.
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four times less frequent than the CFTR p.Phe508del muta-
tion, and twice as frequent as the NPHS2 p.R138Q muta-
tion in the European population [5, 9, 29]. As such, to the 
best of our knowledge, it is the most common mutation 
leading to chronic renal failure in childhood. In accord-
ance with its frequent causal role in nephronophthisis, we 
D2S293 2
8 7 2
5
10
6
2
del
7
5
10
5
2
del
5
10
del
5
2
3
9
wt
7
4
5
10
wt
6
2
7
5
10
del
5
2
8
3
9
wt
7
4
2
3
8
wt
6
1
D2S340
D2S1893
D2S160
D2S363
NPHPI
D2S293
D2S340
D2S1893
D2S160
D2S363
NPHPI
Figure 5: Haplotype analysis of the family F84 with a de novo 
 deletion.
We found no recombination in the NPHP1 region between the two 
paternal chromosomes suggesting that the deletion resulted from 
an intrachromosomal loop formation.
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Figure 6: Dosage quotient of NPHP1 exons determined by QMPSF in 
patients and control subjects.
19
19
12 6
9
USH2AHSD17B3
HSD17B3
A
B
15
12 6
9
USH2A
15
3
3
Figure 7: Electropherograms of either a patient with heterozygous 
deletion (A) or a patient (F106-1) with compound heterozygous 
deletion (B) (in red), superimposed on the electropherograms of a 
control subject (in blue).
While control regions (HSD17B3 and USH2A) show a similar peak 
height in patients and controls, heterozygous deletion reduces the 
peak height by half and a deletion on both alleles (B, patient F106-1, 
exon 19) abolishes it.
found it in the families with juvenile nephronophthisis in 
the homozygous and heterozygous state in 32% and 18%, 
respectively. Such a high NPHP1 mutation rate was found 
in other single center cohorts [9, 30, 31], while a lower 
rate was reported in worldwide cohorts [2], probably due 
to the less stringent clinical inclusion criteria. Although 
the majority of the patients carry the NPHP1 deletion in 
the homozygous state, we found one third of the patients 
with NPHP1 deletions to be compound heterozygous for 
the whole gene deletion and either a point mutation or 
a partial deletion. A similar ratio was reported in other 
cohorts [9, 32], making the identification of NPHP1 dele-
tion in the heterozygous state important. One could argue 
that sequencing of NPHP1 would allow the identifica-
tion of the trans-associated hemizygous mutations and 
thus it is useless to identify the NPHP1 deletion in the 
heterozygous state. Nevertheless, differentiation of the 
homozygous and hemizygous state of the trans-associ-
ated mutations is possible only if parental DNA samples 
are available, and even if they are, it is difficult or even 
impossible to conclude whether the deletion is inherited 
or appeared de  novo. This latter seems to be crucial in 
case of the NPHP1 gene deletion, which – in contrast to 
the vast majority of the recessive mutations or the novel 
3′ partial deletion – is not a founder mutation, but arises 
from independent events [4, 28]. This is very well reflected 
in our study by the detection of a de novo deletion and 
by the very different haplotypes of the deleted alleles. 
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Even among families with homozygous deletion, only the 
consanguineous families carried the same haplotype on 
the two alleles. The independent origin of the deletions 
also explains its similarly high frequency in different geo-
graphic area [9, 30, 31]. Two mechanisms have been pro-
posed to explain the appearance of an NPHP1 deletion: an 
unequal recombination secondary to (1) chromosome mis-
alignment following an intrachromosomal loop formation 
or secondary to (2) unequal crossing over between the two 
homolog chromosomes leading to a deletion on one and 
a duplication on the other homologue [4]. We found no 
crossing over and thus suggest the first mechanism to be 
causal in the family with the de novo deletion (Figure 5). 
The de novo appearance dramatically reduces the risk of 
recurrence among the siblings, but does not abolish it as 
parental mosaicism was found in 4% of families with de 
novo CNV [33]. As the de novo rate of the NPHP1 deletion 
– 1/16 in the present and 1/14 in a previous study [34] – is 
not negligible, it is crucial to verify the carrier status of 
the parents. Furthermore, given the carrier frequency of 
~ 1 : 200 in the general population, one could even con-
sider screening the partners of mutation carriers. All these 
aspects make the detection of the heterozygous NPHP1 
deletion important both for the genetic diagnosis and 
for genetic counseling. However, the carrier status of the 
parents has rarely been investigated [35].
Given the frequency of the NPHP1 deletion and the 
difficulty of its detection by multiple parallel sequenc-
ing, its targeted genetic screening should precede any 
other genetic test once the clinical diagnosis of juvenile 
nephronophthisis is raised [1]. As QMPSF is 3.5 × less 
expensive in our setting than MLPA, and replaces the 
four-step procedure of MLPA by a single one, we tested 
it for the detection of NPHP1 deletion. The diagnosis of 
NPHP1 deletion was primarily established by MLPA and 
confirmed by a second test in all patients. Within this 
cohort, we found both the specificity and the sensitivity 
of QMPSF to be 100% for the detection of both the het-
erozygous and the homozygous NPHP1 deletion. We also 
properly identified a compound heterozygous deletion 
by QMPSF, though our method covers only six out of 20 
exons. To achieve such a high sensitivity and specificity, 
it is essential to properly stop the amplification before 
the saturation and thus to keep the amount of the PCR 
product proportional to the original amount of the tar-
geted sequence. A potential disadvantage of our QMPSF 
method is that it misses those CNVs that are located 
in-between the targeted six exons. Though no such a 
small CNV has been reported thus far in NPHP1, they 
would go undetected by this method. On the other hand, 
though duplications of NPHP1 are not implicated in the 
pathogenesis of nephronophthisis and thus could not be 
investigated, they have been reported in patients with 
autism [36] and are expected to be detectable by QMPSF.
We thus conclude that NPHP1-QMPSF is perfectly 
suitable for the detection of the NPHP1 deletion even in 
the heterozygous state and thus suitable for the clinical 
diagnosis. As the NPHP1 deletion may occur de novo, the 
carrier status of the parents is highly recommended to be 
verified in clinical practice.
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